Wegovy Week by Week: What Your Body Is Actually Going Through

The biggest misconception: week one should feel like something

A common source of anxiety in our prescribers' inboxes goes something like this: "It's been two weeks and I've barely lost anything, is it working?" The honest answer is yes, almost certainly, but not in the way you're looking for yet. The 0.25 mg starting dose exists entirely to let your digestive system adjust. It is not the dose that drives weight loss; it is the dose that makes the next dose tolerable. Expecting dramatic results in the first fortnight sets people up to abandon treatment that was working perfectly well.

What you might actually notice in weeks one and two is subtler: a slightly earlier sense of fullness at mealtimes, food staying on your mind less between meals, or a mild queasiness after eating quickly. Some people notice almost nothing. Both responses are normal. The semaglutide mechanism is already active at 0.25 mg; the appetite-regulating effect on the brain's GLP-1 receptors is real at this dose, it simply hasn't had time to translate into the scale changes people are watching for.

If nausea does arrive in week one, smaller meals, slower eating, and staying upright after food tend to help. This early discomfort is the most common reason people stop prematurely, which is worth knowing before it happens rather than during it.

Weeks four to twelve: when the picture starts to shift

The 0.25 mg phase typically lasts four weeks, after which a prescriber reviews and moves the dose to 0.5 mg. This is when appetite suppression becomes more pronounced for most people. Portion sizes fall without conscious effort. Hunger between meals quietens. Some people describe a noticeable indifference to foods they previously found hard to resist.

Weight loss in this window varies considerably between individuals. The STEP 1 trial, published in the New England Journal of Medicine, followed adults on semaglutide 2.4 mg for 68 weeks alongside lifestyle changes, but participants spent a significant portion of those early weeks on sub-maintenance doses, just as you will. The trial's average figures emerged over the full course. Expecting 15% loss by week twelve misreads the data entirely.

Side effects typically peak around dose increases and then settle within one to two weeks. Moving from 0.5 mg to 1.0 mg, and later to 1.7 mg, each carries a short adjustment window. Loose stools, fatigue and occasional headaches are reported alongside nausea; most people find these manageable and transient. A detailed account of how weeks five and six typically feel is covered on our week five page, including what to do if nausea lingers past the usual window.

Weeks twelve to thirty-two: reaching and establishing the maintenance dose

The standard titration path reaches the 2.4 mg maintenance dose around week sixteen, though this depends entirely on how each dose increase has been tolerated. Rushing titration to reach maintenance faster is not clinically supported and can intensify side effects unnecessarily, the schedule exists for a reason.

From maintenance onward, weight reduction tends to become more consistent and measurable. This is the phase the trial data describes most clearly. Appetite suppression is at its most sustained; many people find their relationship with food shifts in ways that feel less effortful than dieting previously did. Fatigue and GI symptoms, for most, have become background noise rather than active problems by this point.

For a closer look at how week seven specifically lands for many patients (often a first glimpse of the maintenance-dose effect) the week seven overview covers what the shift tends to feel like. The weight loss by week breakdown maps the trial data against realistic individual variation, which is useful context for anyone comparing their progress against published averages.

One practical note for this phase: if you're on a private prescription, your pen arrives tracked, in a plain box, via DPD, exactly the same as every other delivery. The pen itself is pre-filled and pre-set; there is nothing to measure or draw up.

Beyond week thirty-two: what sustained progress actually looks like

The STEP 1 trial's 68-week average of around 15% body-weight reduction tells you something important: weight loss on semaglutide is a long-arc process. Progress between weeks thirty-two and sixty-eight is real but slower than the earlier phase. Plateaus are common and do not indicate the medicine has stopped working; they are a normal feature of the body's adaptive response to a sustained energy deficit.

The NHS semaglutide page notes that the medicine should be used alongside a reduced-calorie diet and increased activity, not as a standalone intervention. Protein adequacy and hydration matter more as appetite suppression deepens, because eating less means the nutritional quality of what you do eat carries more weight. These are conversations worth having with your prescriber, not decisions to make alone.

For those curious about the higher 7.2 mg dose approved by the MHRA in early 2026, or how Wegovy compares overall with other licensed options, the Wegovy overview covers the full picture. Cost is a practical reality for anyone on a private prescription; the Wegovy pricing page sets out what the private market looks like honestly, including what any legitimate price should include. Week nine is also a common inflection point, our week nine guide addresses the questions that tend to surface at that stage.

If you have questions about your own titration or want to understand whether semaglutide is the right fit for your situation, speaking to our prescribers is the place to start. There's no obligation, no algorithm reading your answers, a real clinician reviews every consultation.